Table 3.
Subgroup analysis for teriparatide vs. bisphosphonates for risk of fracture
| Subgroup | No. trials | P value | RR (95% CI) | I-squared |
|---|---|---|---|---|
| Drug of bisphosphonates | ||||
| Alendronate | 4 | 0.022 | 0.51 (0.28, 0.91) | 38.00% |
| Risedronate | 4 | 0.000 | 0.63 (0.51, 0.77) | 10.30% |
| Zoledronic acid | 2 | 0.173 | 0.62 (0.31, 1.23) | 0.00% |
| Sample size of participants | ||||
| No. (≤ 100 of participants) | 4 | 0.008 | 0.37 (0.18, 0.77) | 0.00% |
| No. (> 100 of participants) | 6 | 0.000 | 0.64 (0.53, 0.77) | 1.30% |
| Follow-up | ||||
| = 12 months | 4 | 0.011 | 0.50 (0.29, 0.85) | 0.00% |
| = 18 months | 5 | 0.027 | 0.73 (0.55, 0.96) | 10.90% |
| = 24 months | 1 | 0.000 | 0.56 (0.43, 0.74) | _ |